Source:http://linkedlifedata.com/resource/pubmed/id/12733119
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2003-5-6
|
pubmed:abstractText |
Distinguishing thyroid follicular adenoma from minimally invasive or encapsulated angioinvasive carcinoma can be diagnostically challenging. In some cases, tumors are distorted, fragmented, or stripped of their capsule, and a definitive diagnosis becomes nearly impossible. In other cases, the foci of capsular and/or vascular invasion are subtle, thus making the diagnosis of carcinoma difficult. We developed a microdissection genotyping assay for assessing a panel of tumor-suppressor genes for loss of heterozygosity mutations. The frequency of allelic loss (FAL) in follicular-derived neoplasms correlates with the histologic aggressiveness of the tumor. Furthermore, we calculated the amount of genetic heterogeneity within each tumor, as a second important measure of a tumor's ability for clonal expansion and a surrogate marker for its malignant potential. The follicular adenomas had a low FAL (average 9%) and low intratumoral heterogeneity (5% variability). The minimally invasive and encapsulated angioinvasive carcinomas had an intermediate FAL (average 30%) and intermediate intratumoral heterogeneity (10% variability). The widely invasive carcinomas had a high FAL (average 53%) and high intratumoral heterogeneity (24% variability). Although a larger retrospective study is needed to correlate genotyping studies with patient outcome and prognosis, our results indicate that performing a mutational genotyping assay can stratify tumors into the histologically well-defined categories of adenomas, minimally invasive/angioinvasive carcinomas, and widely invasive follicular carcinomas.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0046-8177
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright 2003 Elsevier Inc. All rights reserved.
|
pubmed:issnType |
Print
|
pubmed:volume |
34
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
375-80
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:12733119-Adenoma,
pubmed-meshheading:12733119-DNA, Neoplasm,
pubmed-meshheading:12733119-DNA Primers,
pubmed-meshheading:12733119-Dissection,
pubmed-meshheading:12733119-Genes, Tumor Suppressor,
pubmed-meshheading:12733119-Genotype,
pubmed-meshheading:12733119-Humans,
pubmed-meshheading:12733119-Loss of Heterozygosity,
pubmed-meshheading:12733119-Minisatellite Repeats,
pubmed-meshheading:12733119-Neoplasm Invasiveness,
pubmed-meshheading:12733119-Polymerase Chain Reaction,
pubmed-meshheading:12733119-Prognosis,
pubmed-meshheading:12733119-Thyroid Neoplasms
|
pubmed:year |
2003
|
pubmed:articleTitle |
A novel microdissection and genotyping of follicular-derived thyroid tumors to predict aggressiveness.
|
pubmed:affiliation |
University of Pittsburgh Medical Center, Pittsburgh, PA and University of Pennsylvania Medical Center, Philadelphia, PA 15213, USA.
|
pubmed:publicationType |
Journal Article
|